<a href="https://laohu8.com/S/ELEV">Elevation Oncology</a> Inc. Announces Regulatory Changes Following Merger and Delisting from Nasdaq
Elevation Oncology Inc. recently announced a significant regulatory update following its merger with Concentra Biosciences, LLC. On July 23, 2025, the company completed a merger, resulting in its shares being delisted from the Nasdaq Stock Market. Elevation Oncology requested Nasdaq to suspend trading of its shares and filed a Notification of Removal from Listing with the SEC. Furthermore, the surviving corporation intends to terminate the registration of its shares and suspend reporting obligations under the Securities Exchange Act. This move marks a change in control, as Elevation Oncology is now a wholly owned subsidiary of Concentra. Additionally, all previous directors have resigned, with new directors and officers from Merger Sub assuming their roles.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elevation Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-026864), on July 23, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。